Friday, 13 September 2013

Turkey Pharmaceuticals and Healthcare Report Q4 2013

Business Monitor International Market Research Reports
Market Reports Online XML Feed 
Make Money From Your Roof

We are paying to help homeowners profit from producing solar power. Find out if your home qualifies for our program today. Sign up!
From our sponsors
Turkey Pharmaceuticals and Healthcare Report Q4 2013
Sep 11th 2013, 00:00

Price: $ 1295  

BMI View: Turkey's pharmaceutical market has posted nominal growth in local currency terms and stemmed the decline in US dollar terms. However, imports continued their precipitous decline year-overyear, with local drugmakers picking up the slack. Continued fiscally-conservative policies by the AKP government have held back pharmaceutical spending by the SSI and kept its growth in check, even as the SSI struggles to overcome its structural deficit. Turkey stands to lose its status as a high-growth emerging market if it maintains its regressive regulatory attitude towards the sector, having been singled out by the PhRMA and Pfizer as stifling growth and market access. Headline Expenditure Projections ? Pharmaceuticals: TRY16.39bn (US$9.11bn) in 2012 to TRY17.16bn (US$9.17bn) in 2013; +4.7% in ...

Complete report details with Table of Contents and more @

Delicious Digg Evernote Facebook Google Bookmarks Google Plus LinkedIn StumbleUpon Tumblr Twitter
You are receiving this email because you subscribed to this feed at

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions

No comments:

Post a Comment